Mr Robb Patryk > Hughes Hubbard & Reed LLP > New York, United States > Lawyer Profile

Hughes Hubbard & Reed LLP
ONE BATTERY PARK PLAZA
NEW YORK, NEW YORK 10004-1482
NEW YORK
United States

Work Department

Product Liability & Toxic Tort Group.

Position

Robb is a trial lawyer and serves as the firm’s Managing Partner. He also is a member of the firm’s Executive Committee – He focuses on complex litigation related to tort and fraud claims involving the sale of consumer, industrial, and medical products and securities.

Career

Robb has over 30 years of experience in the national and international defense of numerous mass torts involving prescription drugs, medical devices, pesticides, asbestos, tobacco, dietary supplements, machinery, blood products, specialty chemicals, motor vehicles and petroleum products. Robb has significant knowledge in particular of the pharmaceutical, medical device, tobacco, and specialty chemical industries, and serves as a trusted advisor to companies in those arenas in navigating the legal and regulatory challenges presented. His many significant matters include the defense of Merck & Co. Inc. in Vioxx and Vytorin litigation, the defense of an oil refiner in MTBE litigation, the defense of Ferro Corp. in multiple, alleged water contamination cases involving 1,4 dioxane, and multiple jury trials for Lorillard Tobacco Company. Robb was Co-Chair of the firm’s Product Liability & Toxic Tort Group from 1999 – 2023.

Languages

English.

Education

New York University School of Law, J.D., 1989 Yale College, B.A., 1985 (magna cum laude).

Lawyer Rankings

United States > Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)

Leveraging expertise throughout the country, including a particularly compelling East Coast and Midwest offering, Hughes Hubbard & Reed LLP is ‘very well-prepared to answer all kind of questions related to product liability matters’, irrespective of geographical location. The team is best-known for its  work in federally-regulated industries, and as well as its ‘stellar pharmaceuticals offering’, is also accomplished at handling matters relating to alleged damage caused by tobacco and speciality chemicals. Drawing upon trial and appellate litigation prowess, Kansas City-based partner James Berger  is adept at handling all aspects of complex litigation in multiple state and federal courts throughout the country; he continues to spearhead the firm’s efforts on behalf of tobacco company R.J.Reynolds in the Kent filter litigation. Best-known for their life sciences and medical devices expertise, New York-based practitioners Robb Patryk  and James C. Fitzpatrick co-head the overarching products liability and toxic tort offering.

United States > Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices

Lauded for its ‘deep legal, regulatory, and scientific knowledge’, Hughes Hubbard & Reed LLP provides ‘unparalleled client service’ to clients, often working collaboratively with other counsel in a “virtual law firm” setting to defend pharma and medical device companies against high-profile mass tort claims. The firm has also gained a market-leading reputation for its ability to effectively co-ordinate cross-border litigation, providing ‘very efficient, smooth and productive communication and work’, as a result of its ‘close familiarity with multinationals’ culture and requirements as well as with foreign law firms’. James C. Fitzpatrick  and Charles W. Cohen  have been key to this success and have both developed ‘vast international experience in different jurisdictions’ over the years. They both also ‘have exceptional skills to present creative and strong arguments’, with Fitzpatrick, in particular, noted for his ‘cutting-edge abilities on the scientific aspects’, and ability to effectively develop strong arguments working with medical and science experts. Robb Patryk  co-heads the team with Fitzpatrick and as part of his broad product liability practice regularly handles pharma-related disputes.